Trial Profile
A study evaluating incidences of tumor lysis syndrome in symptomatic patients with multiple myeloma with renal dysfunction treated with Bortezomib.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Oct 2017
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 28 Oct 2017 New trial record